Within the next few weeks the results of a study conducted by Radient in collaboration with the Mayo Clinic comparing its Onku-Sure test kit with one of its major competitors are expected to be released. If Onku-Sure is shown to be as effective or even more effective than the competitive product Radient has the potential to be a takeover target by a big pharma company. Estimates of a takeover price have been as high as the $10.00-$15.00/share range.
Review the following information and you may decide that buying Radient shares at the current depressed share price is a very acceptable risk/reward scenario.
Len Bogner: Radient Pharmaceutical Update - March 4,2011